Forbion is a global venture capital firm dedicated to advancing groundbreaking biotech innovations and other sustainable solutions that improve the health of people and our planet.
€5bn
Across 11 funds
€1.2bn
Forbion Growth Opportunities Fund III
€890m
Forbion Ventures VII
€180m
Forbion BioEconomy I
Forbion Ventures builds and supports pre-clinical and early clinical companies
Company building and supporting breakthrough innovations
Forbion Growth's investment focus is on providing capital for clinical stage drug development, primarily as private growth capital, and selectively as crossover and public investments.
Company expansion
Private growth capital, crossovers, PIPE / VPE / Block trades
Forbion runs a joint venture with BioGeneration Ventures (BGV). BGV together with its FIRST Fund, is the early-stage strategy on our platform.
Pre-creation / Pre-seed
From company formation through early-stage scaling
Forbion BioEconomy focuses on innovative companies that leverage biotechnology to clean and feed the planet across four sectors, Food, Agriculture, Materials and Environmental Technologies.
Ventures Fund
Enable, Grow
Series A+ rounds
Human Health
Azafaros
Azafaros aims to be a beacon of hope for patients living with severe rare genetic diseases and their families.
Human Health
VectorY
Planetary Health
Genomines
Genomines is pioneering the future of global metal extraction with efficient, plant-based metal farming.
Since impacting the future is our ethos, we integrate ESG principles into our human and planetary health investments by focusing on patient impact, societal benefits, and sustainability all with the aim of achieving positive change.
The Forbion team consists of over 50 people of diverse nationalities across three offices in The Netherlands, Germany and the US.
Forbion Portfolio Company Orbis Medicines Named in 2025 Endpoints 11
September 19, 2025
VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement
September 18, 2025
PDF 156.8 KB
Download